They showed effective BBB delivery, and they significantly prolonged brain tumor-bearing animal survival by the simultaneous inhibition of two major brain cancer markers, c-Myc and EGFR/EGFRvIII, that are present in a number of mutation-bearing GBM variants [1,4,5,6,7], with concomitant suppression of an immune checkpoint to boost tumor immune surveillance. The gene discussed is MYC; the disease is brain cancer.